Veru Inc.

VERU

US92536C1036

Personal Products

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.33 ^USD	-2.92%		-18.40%	+84.72%

May. 08	Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	MT
May. 08	Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024

Veru Inc. Provides Earnings Guidance for the Year 2021

December 09, 2020 at 08:00 am EST

Veru Inc. provided earnings guidance for the year 2021. The company expects fiscal year 2021 revenue generation will continue to grow robustly for what could be another record year.

Latest news about Veru Inc.

Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	May. 08	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	May. 08
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	May. 06	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	CI
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	Mar. 12	CI
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	Feb. 20	CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024	Feb. 08
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	Jan. 08	CI
Transcript : Veru Inc. - Special Call	Jan. 04
Veru Prices $33 Million Offering; Shares Fall	Dec. 14	MT
Veru Launching Public Offering of Shares	Dec. 13	MT
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 08	CI
North American Morning Briefing : Stock Futures, -2-	Dec. 04	DJ
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	23-10-04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	23-09-26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	23-09-11	CI
Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	23-08-14	MT
Transcript : Veru Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (VERU) VERU Posts Q3 Revenue $3.3M	23-08-10	MT

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

2024-05-16 - GLP-1 Based Therapeutics Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Veru Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.33 USD

Average target price

3.667 USD

Spread / Average Target

+175.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Birth Control Products

	1st Jan change	Capi.
VERU INC.	+84.72%	195M
CUPID LIMITED	+77.14%	319M
KAREX	+11.64%	181M
THAI NIPPON RUBBER INDUSTRY PUBLIC CO., LTD.	+9.28%	86.47M
SAGAMI RUBBER INDUSTRIES CO., LTD.	+5.01%	65.75M

Birth Control Products

Veru Inc.

Equities

VERU

US92536C1036

Personal Products

Veru Inc. Provides Earnings Guidance for the Year 2021

Latest news about Veru Inc.

Chart Veru Inc.

Company Profile

Income Statement Evolution

Ratings for Veru Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Birth Control Products